Pharyngoesophageal foreign bodies (FBs) 
Introduction
Pharyngoesophageal foreign bodies (FBs) are a common otolaryngologic problem. [1] [2] [3] Most are managed endoscopically, but when not easily retrieved, they pose a significant challenge. We present such a case, involving a man with an extraluminal esophageal FB that migrated through the pharyngoesophageal segment. The use of intraoperative, real-time ultrasound (US) to guide endoscopic extraction of the FB allowed quick, safe treatment and prevented the need for a transcervical approach and its potential morbidities.
Existing literature on intraoperative ultrasound for FB retrieval describes its value in localizing a submucosal fish bone, enabling the creation of a well-positioned mucosal incision to afford direct endoscopic visualization of the FB. 4 To the best of our knowledge, this is the first report of a case of submucosal chicken bone removal under US visualization without traditional endoscopic visualization of the FB.
Case report
A 59-year-old man presented to the Emergency Department with 1 day of left-sided throat pain after inadvertently swallowing a presumed chicken bone. He sought medical attention after developing increasing pain and fever over the next day. On examination, the patient was not in acute distress, nor did he have stridor or voice change. He had a low-grade fever but was hemodynamically stable. The neck was without erythema, edema, or subcutaneous emphysema. The remainder of the head and neck examination was unremarkable. Flexible nasopharyngoscopy revealed a small abrasion of the left tongue base and mild edema of the left arytenoid, but no FB was identified within the oropharynx or hypopharynx. There was no appreciable submucosal fullness or abnormality.
Contrast-enhanced computed tomography (CT) of the neck demonstrated a 3-cm linear, radio-opaque FB in the postcricoid region abutting the left cricothyroid joint (figure 1). Consent was obtained for operative removal under general anesthesia. During rigid direct laryngoscopy and esophagoscopy, mild mucosal injury was appreciated in the postcricoid region, although no intraluminal FB was seen. A nasogastric tube was inserted under direct vision; the patient was kept nil per os (NPO) and started on antibiotics. A repeat neck CT confirmed an unchanged position of the FB.
The next day, the patient was taken for repeat operative esophagoscopy and possible transcervical retrieval of the FB. Again, the FB was not encountered endoscopically despite attempts with both the rigid cervical esophagoscope and the Dedo-Pilling laryngoscope.
Before resorting to an open approach, we used intraoperative US to locate the FB. With the use of a standard US probe, the relationship of the FB to the ACCLARENT AERA ® Eustachian Tube Balloon Dilation System GO TO THE SOURCE.
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Caution: Federal (US) law restricts the sale, distribution or use of these devices to, by or on the order of a physician. Third party trademarks used herein are trademarks of their respective owners. This site is intended for visitors from the United States and published by Acclarent, Inc., which is solely responsible for its contents. Lee, RandaLL, Kuhn rigid endoscope was evident (figure 2). It was oriented longitudinally in the cervical soft tissue, outside and anterior to the pharyngoesophageal lumen. Continuous US imaging with a SonoSite HFL38 transducer with a frequency of 6 to 13 MHz (Fujifilm SonoSite; Bothell, Wash.) was performed by the US technician in real time, allowing the laryngologist to view the relationship of the cupped forceps to the FB. The Dedo-Pilling laryngoscope was used instead of the rigid esophagoscope because the larger working channel allowed a better angle of approach for the endoscopic forceps.
No measurements were made, and no separate incision was created because the angle of the endoscope allowed US visualization of the FB just distal to the tip of the laryngoscope. The endoscopic forceps were advanced until US showed that only a thin layer of soft tissue separated them from the tip of the FB. This layer of intervening tissue was then opened with the endoscopic forceps, which was then advanced into the submucosal tissue to grasp the tip of the FB under real-time US visualization.
The linear FB was retrieved in one piece (figure 3) with no fragments visible on repeat US. There was minimal trauma to the intraluminal mucosal and submucosal site of FB removal. The patient remained NPO over the next 2 days to promote closure of the intraluminal defect and had resolution of his pain. A videofluoroscopic swallow study performed on the third postoperative day demonstrated no extravasation. The patient's diet was advanced without difficulty, and he experienced full recovery after discharge.
Discussion
Pharyngoesophageal FB is a common problem in both children and adults. Up to 80% of adult FBs are fish bones, which have a dangerous predilection given their potential to penetrate tissue and cause additional injury to underlying structures. 1, 3 While in this case, the FB was presumed to be a chicken bone and not a fish bone, the same penetrating tendency applies.
In a case series of more than 2,000 esophageal FBs by Hsu et al, 2 patients developed esophageal perforations requiring removal of the FB through an external approach. 3 In another series, Loh et al found that of patients with major complications (including esophageal perforation), 90% had a fish bone FB as compared to 70% of those with minor complications. 5 Perforation of the esophagus by an FB may predispose a patient to further, more catastrophic complications. Pang et al reported a case in which an ingested FB migrated out of the esophageal lumen and punctured the common carotid artery, causing a retropharyngeal hematoma. 6 Expeditious treatment of FB is key to minimizing secondary injuries, as there is evidence that increased 
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IntraoperatIve ultrasound-guIded retrIeval of an extralumInal pharyngoesophageal foreIgn body time of impaction of FBs is related to increased risk of complications, including esophageal perforation, extraluminal migration, mediastinitis, abscess, and vascular injury. [5] [6] [7] [8] [9] [10] Patients have been found to have a greater than ten-fold chance of developing major complications from an esophageal FB if the FB had been impacted for more than 24 hours. 5 Such was the case in multiple reports of complicated FBs, including a case of a fish bone that had migrated to the subcutaneous tissues causing tenting of the skin, several cases of thyroid abscess related to FB, and a case of a single fish bone FB that caused injury to both the carotid artery and jugular vein. [6] [7] [8] [9] [10] Migrated or complex FBs often require a transcervical approach for retrieval. [6] [7] [8] [9] [10] Intraoperative, real-time US is a minimally invasive and readily available adjunct to rigid endoscopy that may obviate the need for an open approach to access extraluminal FBs or other pathology. 4 While use of US in esophageal FB localization before endoscopic retrieval has been described, to the best of our knowledge, this is the first report of real-time intraoperative US used to retrieve an extraluminal FB.
Intraoperative US was used by Baba et al to locate a 2.4-cm fish bone in the upper esophageal submucosa. 4 They were able to measure the distance from the endoscopic forceps to the fish bone, which guided the placement of a mucosal incision. Without the assistance of US, the FB was exposed and removed endoscopically through the mucosal incision.
In our case, the FB was a chicken bone rather than a fish bone, as determined by history, and was retrieved using US guidance only without the creation of a mucosal incision or traditional endoscopic visualization of the FB at any time. The use of US enabled localization of an entirely extraluminal FB and guided uncomplicated endoscopic retrieval, thereby circumventing the risks associated with neck exploration.
Limitations of this method include patient factors, equipment and personnel availability, and surgeon preference. Endoscopic FB retrieval in a patient with a FB located more distally may be complicated by a more difficult angle of approach and the inability to use a laryngoscope with a larger working channel. Obese patients may present a greater challenge for US, given the increased depth of the field and potentially increased noise in the image. If there is concern for complications such as vascular injury, the endoscopic approach does not provide the opportunity to address and control these potential problems.
This method also depends on the availability of an appropriate ultrasound machine with the proper transducer, although these tend to be widely available.
Depending on the operator's familiarity with the equipment, the use of real-time US may require the presence of a radiologist or, as in our case, a skilled US technician. The quality of visualization is user-dependent, so the abilities of a radiologist or technician are a great advantage.
US also allows guidance in only one dimension at a time, so adjusting one's position in three-dimensional space using US can be challenging. Lastly, because the surgeon is essentially performing an endoscopic surgery while relying solely on US for visualization, he or she must be quite skilled at endoscopy and comfortable interpreting US to use it to efficiently guide the procedure.
US could also be used intraoperatively to define the relationship between the FB and other anatomic obstacles, including vascular structures, hematoma, or abscess cavities, as well as to confirm complete removal of fragmented FBs. Because it can be difficult to determine the relationship of a migrated FB to the esophageal lumen on imaging when the esophagus is collapsed, intraoperative US performed while the esophagus is distended with an endoscope can provide information regarding the position of an FB that cannot be obtained otherwise. Therefore, we suggest consideration of real-time US-assisted endoscopy in appropriately selected cases of CT-confirmed, complicated FBS.
